Clopidogrel and Aspirin Interaction Study-2

Phase 4CompletedNCT01341964

Population Health Research Institute302 enrolled

Overview

Clopidogrel and aspirin are commonly used in combination to prevent heart attacks and to prevent blockage of stents. Both clopidogrel and aspirin work by preventing platelets (sticky cells that circulate in the blood) from forming blood clots in the arteries supplying oxygen to the heart and in stents. The investigators hypothesize that aspirin 325mg compared with aspirin 81 mg will increase blood levels of the active metabolite of clopidogrel in patients with a history of coronary artery disease who receive a 600mg loading dose of clopidogrel.

Eligible patients will be randomized to receive clopidogrel 600mg + aspirin 325mg (Group A) or clopidogrel 600mg + aspirin 81mg (Group B). Patients will be fasted for at least 8 hours prior to study drug administration. Blood samples will be collected at 1 hour after study drug administration for measurement of clopidogrel active metabolite levels and genotyping.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

302

Conditions

Drug Action Increased

Interventions

ClopidogrelDRUG

600mg (2 pills)

AspirinDRUG

325mg (1 pill)

AspirinDRUG

81mg (1 pill)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Stable patients \>1 month post ACS (including ST elevated myocardial infarction, non-ST elevated myocardial infarction or unstable angina) or stent * Receiving regular ASA (81mg/d) and clopidogrel (75mg/d) for at least 1 week * Written informed consent Exclusion Criteria: * Age \< 18 years * Liver disease with ALT or bilirubin \>2x upper limits of normal (ULN)\* * Renal impairment with creatinine clearance \<30 ml/min\* * Deemed to be at high risk of bleeding (e.g., recent bleeding, platelet count\<100x109/L or hemoglobin \<100g/L)\* * Anticoagulant or NSAID therapy within the last 5 days * Antiplatelet agent other than aspirin and clopidogrel within the last 10 days * Uncontrolled hypertension (\>=180/110mmHg) * within 3 months of planned randomization

Locations (1)

Population Health Research Institute, Hamilton General Hospital

Hamilton, Ontario, Canada

Outcomes

Primary Outcomes

Blood Concentration of the Active Metabolite of Clopidogrel

Clopidogrel active metabolite concentration will be measured by liquid chromatography tandem mass spectrometry (LC/MS) methods.

Time frame: 1 hour after loading dose of study medications

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.